Generics' Bid To Limit IP Loss 'Makes No Sense,' Judge Says
A Delaware federal judge on Monday extended his finding that generic-drug makers infringed valid claims for patents covering Teva's cancer drug Bendeka to dozens of untried patent claims, saying pretrial agreements...To view the full article, register now.
Already a subscriber? Click here to view full article